粪便微生物群移植治疗帕金森病:一项随机临床试验
这项在芬兰4家医院开展的双盲、安慰剂对照随机临床试验,于2020年11月至2023年6月纳入48例伴肠道菌群失调的帕金森病患者,按2:1随机接受单次结肠镜粪菌移植或安慰剂。6个月时主要终点MDS-UPDRS I-III部分评分变化组间无显著差异(0.97分,95%CI -5.10至7.03,P=.75),粪菌移植组胃肠道不良事件更常见(16例[53%] vs 1例[7%],P=.003)。作者结论为粪菌移植安全但未带来有临床意义的改善。
要点
- 6个月时MDS-UPDRS I-III评分变化组间无显著差异(0.97分,95%CI -5.10至7.03,P=.75)。
- 粪菌移植组胃肠道不良事件更常见(16例[53%] vs 1例[7%],P=.003)。
- 次要结局和事后分析显示安慰剂组多巴胺能药物增加更强、部分运动和非运动结局改善。
核心结论
- 粪菌移植安全但未提供有临床意义的改善。
- 作者认为需进一步研究,例如通过改良粪菌移植方法或肠道清洗,探讨供体微生物群组成和菌群失调转归对帕金森病运动和非运动结局及药物需求的具体影响。
研究设计与样本
- 双盲、安慰剂对照、随机临床试验,2020年11月至2023年6月在芬兰4家医院开展,随访12个月。
- 纳入35至75岁、Hoehn & Yahr分期1-3期、轻中度症状负担且粪便微生物群失调的帕金森病患者。
- 筛查229例,48例随机,47例接受干预;1例因帕金森病症状加重中止,2例在分析前被排除,45例纳入意向性治疗分析。
- 参与者按2:1比例随机接受经结肠镜给予的粪菌移植或安慰剂。
主要发现
- 主要终点为6个月时MDS-UPDRS I-III部分(III部分停药状态)评分变化,组间无显著差异(0.97分,95%CI -5.10至7.03,P=.75)。
- 胃肠道不良事件在粪菌移植组更常见(16例[53%] vs 1例[7%],P=.003)。
- 次要结局和事后分析显示安慰剂组多巴胺能药物增加更强、部分运动和非运动结局改善更明显。
- 粪菌移植后微生物群变化更明显但因供体而异;菌群失调状态在安慰剂组更频繁逆转。
- 安慰剂组中位(IQR)年龄为65(52.5-70.0)岁,粪菌移植组为66(59.25-69.75)岁;男性分别为9例(60.0%)和16例(53.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步研究,例如通过改良粪菌移植方法或肠道清洗,探讨供体微生物群组成和菌群失调转归对帕金森病运动和非运动结局及药物需求的具体影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models. OBJECTIVE: To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn & Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis. INTERVENTION: Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy. MAIN OUTCOMES AND MEASURES: The primary end point was the change of Movement Disorder Society Unified Parkinson's Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs). RESULTS: The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, -5.10 to 7.03, P = .75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%]; P = .003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group. CONCLUSIONS AND RELEVANCE: FMT was safe but did not offer clinically meaningful improvements. Further studies-for example, through modified FMT approaches or bowel cleansing-are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04854291.
引用
- Scheperjans F, Levo R, Bosch B, et al. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 39073834. doi:10.1001/jamaneurol.2024.2305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。